These studies show significant advantages for PSMA-radioligands in comparison to other nuclear medicine diagnostic methods like 11C- or 18F-Cholin-PET for the diagnosis, patient management and treatment of prostate cancer patients [13,14,15,16,17,18]. This evidence concerns the gene FOLH1 and Familial prostate cancer.